In this ChatTime we brought together the CEO’s of three of Britain’s most exciting Biotech’s that have recently or will recently close their Seed rounds with o2h ventures. All three companies are planning Pre-A or A funding rounds and/or Pharma/Biotech collaborations in 2021.
Ph.D. in Theoretical Physics from King’s College London. KUANO’s co-founder and an expert in quantum physics. Spent the past 10 years working on string theory and many body quantum physics simulations, the latter underlying the technology spearheaded at KUANO.
Tim is a highly motivated and driven individual with 25 years of experience of working in blue chip big pharma, specialty pharma and biotech. He has held CEO, business development and management positions, including at board level, in companies with interests in neuroscience, cancer, diabetes and ophthalmology.
Myriam has significant experience in drug delivery and biopharmaceuticals in both academia and industry. Prior to Spirea, Myriam was a Senior Postdoctoral Research Associate at the University of Cambridge, Nanoscience Centre.